Venaflo Ptfe Vascular Graft, Venaflo Graft with Carbon, Venaflo Vascular Graft
510(k) K981079
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK981079 | Date7 May 1998 | StatusActive |
Recalls
No FDA recalls found in the data synced 22 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- 510(k) Number
- FDA Product Code
- DSY
- Device Class
- Class II
- Regulation
- 21 CFR Part 870.3450
- Advisory Committee
- Cardiovascular
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 1 Oct 2026
The Venaflo PTFE Vascular Graft is classified as a Prosthesis, Vascular Graft, of 6mm and Greater Diameter under FDA nomenclature. These grafts are constructed from expanded polytetrafluoroethylene (ePTFE) and are designed to serve as synthetic conduits for vascular access, facilitating blood flow in cardiovascular applications. The Venaflo Graft with Carbon variant incorporates a carbon-lined lumen to enhance surface properties, while the standard graft features a cuffed venous end to improve patency and reduce stenosis. Both variants are intended for use as subcutaneous arteriovenous conduits.
These grafts are supplied sterile and intended for single-use in hemodialysis and vascular access procedures. They are regulated under FDA 510(k) clearance (K981079) and fall under Class II medical devices (DSY product code). The grafts are available in multiple sizes and configurations, as indicated by their registration numbers, and are designed for use in cardiovascular settings. Storage and handling must comply with sterile medical device protocols to ensure integrity prior to use.
Other devices from Impra, Inc.
Questions
AI-generated answers, 1 Oct 2026
What is the Venaflo PTFE Vascular Graft used for?
The Venaflo PTFE Vascular Graft is designed as a synthetic conduit for vascular access in cardiovascular applications. It facilitates blood flow in hemodialysis and arteriovenous (AV) conduit procedures, helping to maintain patency and reduce stenosis. The standard graft features a cuffed venous end, while the Venaflo Graft with Carbon includes a carbon-lined lumen to improve surface properties, both tailored for subcutaneous AV access.
How is the Venaflo PTFE Vascular Graft supplied and what are its sterility and reuse details?
The Venaflo PTFE Vascular Graft is supplied sterile and is intended for single-use only. This ensures patient safety by preventing contamination and cross-infection. The grafts are not designed for reuse, as repeated use could compromise sterility and integrity, potentially leading to adverse clinical outcomes.
What sizes and configurations are available for the Venaflo PTFE Vascular Graft?
The Venaflo PTFE Vascular Graft is available in multiple sizes and configurations, categorized by specific registration numbers. These include variants for both standard ePTFE grafts and the carbon-lined version, all designed for 6mm and greater diameter applications. The exact sizes and configurations can be identified through the registration numbers listed in the FDA database.
How should the Venaflo PTFE Vascular Graft be stored?
The Venaflo PTFE Vascular Graft must be stored according to sterile medical device protocols to maintain its integrity before use. This includes keeping it in a sealed, sterile packaging until the time of procedure, protecting it from contamination, moisture, and physical damage. Proper storage ensures the graft remains sterile and functional for its intended single-use application.
What regulatory pathway does the Venaflo PTFE Vascular Graft follow?
The Venaflo PTFE Vascular Graft is regulated under the FDA’s 510(k) clearance pathway, specifically with clearance number K981079. It is classified as a Class II medical device under the DSY product code, which pertains to Prosthesis, Vascular Graft, of 6mm and Greater Diameter. This classification indicates that the device has undergone evaluation to ensure its safety and effectiveness for its intended use in vascular access procedures.